Move Over, Methotrexate: Could Upadacitinib Be Rheumatoid Arthritis’ New Shining Star?
Methotrexate is one of the most common drugs used to treat rheumatoid arthritis (RA). When used early, disease-modifying antirheumatic drugs (DMARDs) can be clinically...
Rheum Round-up: Sarilumab Flops in COVID-19, RA TNFi Termination and Body Weight, and more
Here are the top stories recently covered by DocWire News in the rheumatology section. In this edition, read about sarilumab in COVID-19, glucocorticoids in rheumatoid...
Inflammatory Arthritis Patients Present with Musculoskeletal Symptoms Before Diagnosis
Patients who eventually go on to be diagnosed with inflammatory arthritis (IA) often present with musculoskeletal symptoms, infections, and comorbidity leading up to their...
Overweight And Underweight Are Both Risk Factors for TNFi Treatment Discontinuation in RA
Rheumatoid arthritis (RA) patients with either a low or high body mass index (BMI) are more likely than normal weight RA patients to discontinue...
Self-Harm Risk Greater Among Patients with These Rheumatic Diseases
A recent study explored the risk of self-harm among patients with different rheumatic diseases. Patients with rheumatoid arthritis (RA), osteoarthritis (OA), and fibromyalgia may...
Interview: Using Digital Technology to Collect Rheumatoid Arthritis Patient Data
Now more than ever in the COVID-19 era, the use of digital technology in health care is increasingly important. In the Digital Tracking of...
Rheum Round-up: Ixekizumab’s Extended FDA Approval, RA Biosimilars Compared, and more
Here are the top stories recently covered by DocWire News in the Rheumatology section. In this edition, read about the extended approval of ixekizumab,...
